Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | A389T |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | FGFR2 A389T lies within the transmembrane domain of the Fgfr2 protein (UniProt.org). A389T results in proliferation similar to wild-type Fgfr2 in a competition assay (PMID: 34272467) and is not transforming in culture in one study (PMID: 18552176), but increased transformation activity in cultured cells in another study (PMID: 34272467), and therefore, its effect on Fgfr2 protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 A389T |
Transcript | NM_000141.5 |
gDNA | chr10:g.121515239C>T |
cDNA | c.1165G>A |
Protein | p.A389T |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_017015923 | chr10:g.121503848C>T | c.1165G>A | p.A389T | RefSeq | GRCh38/hg38 |
NM_000141 | chr10:g.121515239C>T | c.1165G>A | p.A389T | RefSeq | GRCh38/hg38 |
NM_000141.5 | chr10:g.121515239C>T | c.1165G>A | p.A389T | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121515239C>T | c.1165G>A | p.A389T | RefSeq | GRCh38/hg38 |
NM_001320658 | chr10:g.121515239C>T | c.1165G>A | p.A389T | RefSeq | GRCh38/hg38 |
XM_024447889.2 | chr10:g.121503848C>T | c.1165G>A | p.A389T | RefSeq | GRCh38/hg38 |
NM_001320658.2 | chr10:g.121515239C>T | c.1165G>A | p.A389T | RefSeq | GRCh38/hg38 |
XM_024447889.1 | chr10:g.121503848C>T | c.1165G>A | p.A389T | RefSeq | GRCh38/hg38 |
NM_001320658.1 | chr10:g.121515239C>T | c.1165G>A | p.A389T | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 A389T | Advanced Solid Tumor | predicted - sensitive | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with AZD4547 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 A389T | Advanced Solid Tumor | predicted - sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with Truseltiq (infigratinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 A389T | Advanced Solid Tumor | predicted - sensitive | Erdafitinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with Balversa (erdafitinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 A389T | Advanced Solid Tumor | predicted - sensitive | Futibatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with Lytgobi (futibatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 A389T | Advanced Solid Tumor | predicted - sensitive | Pemigatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with Pemazyre (pemigatinib) in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |
FGFR2 A389T | Advanced Solid Tumor | predicted - sensitive | E7090 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing FGFR2 A389T were sensitive to treatment with E7090 in culture, demonstrating reduced cell viability (PMID: 34272467). | 34272467 |